The maximum tumor growth rate predicts clinical outcomes of patients with small‐cell lung cancer undergoing first‐line chemotherapy plus immune‐checkpoint inhibitor therapy
Abstract Background Currently, no biomarkers can accurately predict survival outcomes in patients with SCLC undergoing treatment. Tumor growth rate (TGR; percent size change per month [%/m]) is suggested as an imaging predictor of response to anti‐cancer treatment. We aimed to evaluate the predictiv...
Main Authors: | Xiang Chen, Xueyuan Chen, Tingting Liu, Ting Zhou, Gang Chen, Huaqiang Zhou, Yan Huang, Wenfeng Fang, Yunpeng Yang, Ningning Zhou, Likun Chen, Silang Mo, Li Zhang, Yuanyuan Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-04-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5611 |
Similar Items
-
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy
by: Vito Longo, et al.
Published: (2024-01-01) -
Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
by: Yulong Chen, et al.
Published: (2023-09-01) -
Anlotinib plus platinum‐etoposide as a first‐line treatment for extensive‐stage small cell lung cancer: A single‐arm trial
by: Pengbo Deng, et al.
Published: (2022-10-01) -
An In Situ Chemotherapy Drug Combined with Immune Checkpoint Inhibitor for Chemoimmunotherapy
by: Xinyuan Yuan, et al.
Published: (2023-12-01) -
Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
by: Margaret Cupit-Link, et al.
Published: (2023-09-01)